Drug Therapy, B-Adrenoceptor Antagonists:New Drugs & New Indications
NEJM 305:500-506, Frishman,W.H., 1981
Midodrine, A New Agent in the Management of Idiopathic Orthostatic Hypotension & Shy-Drager Syndrome
Mayo Clin Proc 56:429-433, Schirger,A.,et al, 1981
Diagnosis & Treatment, Physiologic & Pathologic Tremors
Ann Int Med 93:460-465, Jankovic,J.,et al, 1980
Metoprolol in Essential Tremor
Arch Neurol 37:596-597, Newman,R.R.,et al, 1980
Treatment Of Migraine With Metoprolol
NEJM 303:156-157, Ljung,O., 1980
Proximal Myopathy During Beta-blockade
BMJ 2:1331-1332, Forfar,J.C.,et al, 1979
Beneficial Effect of Propranolol in Familial Ataxia
Ann Neurol 5:207, Braham,J.,et al, 1979
Organic Brain Syndrome with Propranolol
NEJM 300:366, Kurland,M.L., 1979
Metopropol For Essential Tremor
NEJM 301:331, Britt,C.W.Jr.,et al, 1979
Treatment Of Essential Tremor With Metopropol
NEJM 301:1005, Ljung,O., 1979
Successful Treatment of Narcolepsy with Propranolol
Arch Neurol 36:650-651, Kales,A.,et al, 1979
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979
Seizures & Intraventricular Conduction Defect in Propranolol Poisoning
Ann Int Med 91:860-862, Buiumsohn,A.,et al, 1979
Propranolol for Severe Post-head Injury Action Tremor
Neurol 28:197, Ellison,P.H., 1978
Newer Concepts in Management of Migraine Headaches
J Med Soc N J 74:11, Haidri,N.H.,et al, 1977
Posttraumatic Dysautonomic Cephalgia
Arch Neurol 32:649, Vijayan,N.,et al, 1975
Non-Beta Blocking Action of Propranolol
NEJM 293:988, Koch-Weser,J., 1975
Efficacy of Chronic Propranolol Therapy in Action Tremors of the Familial, Senile or Essential Varieties
NEJM 290:984, Winkler,G.,et al, 1974
Ptosis-Toxiocology of the Eye
p 814, , 1974
Treatment of Essential Tremor with Propranolol
Lancet 205, Jan1973., , 1973
Treatment of Parkinsonism
NEJM 287:1047, Young,R.R., 1972
Benign Essential Tremor
Lancet 471, 1972 Sept., , 1972
Isolated Ophthalmic Migraine:Its Frequency, Mechanism & Diff. Diagnosis
Neuro-Ophthalmol 1972-Bascom Palmer Instit Symp, Ed, J. S. Smith., Hedges,T., 1972
Combined Treatment of Parkinsonian Tremor with Propranolol & Levodopa
J Neurol Sci 14:491, , 1971
Monocular Diplopia:Its Characteristics & Response to Guanethidine
Am J Ophthalmol 63:459, Hales,R., 1967
Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025
Severe Myotonic Crisis Resembling Malignant Hyperthermia
Neurol 104:e213497, Wadhwani,A.R.,et al, 2025
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Comparative Effects of Drug Interventions for the Acute Management of Migraine Episodes in Adults:Systematic Review and Network Meta-Analysis
BMJ 386:e080107, Karlsson,W.K.,et al, 2024
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
EMA401, An Orally Administered Highly Selective Angiotensin II Type 2 Receptor Antagonist, as a Novel Treatment for Postherpetic Neuralgia: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
Lancet 383:1637-1647, Rice, A.C.,et al, 2014
Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency
JAMA 310:2435-2442, Lam, J.R.,et al, 2013
Multimodal Imaging of Reversible Cerebral Vasoconstriction Syndrome: A Series of 6 Cases
AJNR 33:1403-1410, Marder, C.P.,et al, 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Use of Angiotension Receptor Blockers and Risk of Dementia in a Predominantly Male Population: Prospective Cohort Analysis
BMJ 340:141-147, 111, Li,N.-C.,et al, 2010
New Drugs in Migraine Treatment and Prophylaxis: Telcagepant and Topiramate
Lancet 376:645-655, Edvinsson,L. &Linde,M., 2010
Assessment of Potential Drug Interactions in Patients with Epilepsy: Impact of Age and Sex
Neurol 72:419-425, Gidal,B.E.,et al, 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009